Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Cigna is a diversified healthcare services company operating primarily through Evernorth Health Services (pharmacy benefit management, specialty pharmacy, care delivery) and Cigna Healthcare (medical insurance for employers and individuals). The company manages ~193 million customer relationships globally, with Evernorth generating approximately 70% of revenue through its pharmacy services platform processing $200B+ in annual drug spend. Competitive position centers on integrated capabilities combining PBM economics, specialty pharmacy margins, and medical cost management.
Cigna generates revenue through two primary mechanisms: (1) Evernorth captures pharmacy spread (difference between reimbursement from payers and payments to pharmacies), manufacturer rebates, specialty pharmacy dispensing margins, and care management fees on $200B+ annual pharmacy spend; (2) Cigna Healthcare earns medical loss ratio-based margins by collecting premiums and managing medical costs below actuarial targets, targeting 80-85% MLR. Pricing power derives from formulary control, integrated care delivery reducing total cost of care, and employer relationships spanning both PBM and medical coverage. The company's 9.5% gross margin reflects high-revenue/low-margin PBM economics, while 14.6% ROE demonstrates capital efficiency through float management and operational leverage.
Evernorth pharmacy script volume growth and specialty pharmacy penetration rates (higher margin mix)
Medical loss ratio performance in Cigna Healthcare segment - target 80-85% range, with 100bps movement materially impacting earnings
PBM client retention rates and new business wins (multi-year contracts create revenue visibility)
Pharmacy pricing dynamics including generic dispensing rates, biosimilar adoption, and manufacturer rebate agreements
Medicare Advantage membership growth and Star Ratings (4+ stars unlock bonus payments)
Capital deployment through share repurchases ($5-8B annual authorization capacity) and M&A activity
Regulatory risk from potential PBM reform legislation targeting spread pricing, rebate transparency, and vertical integration - could compress Evernorth margins by 200-400bps if forced to pass through all rebates
Medicare Advantage rate pressure as CMS adjusts benchmark payments and implements prior authorization restrictions - affects 15-20% of medical membership
Biosimilar and generic drug adoption accelerating faster than expected, reducing total pharmacy spend and rebate pools
Political risk from single-payer healthcare proposals or public option expansion reducing commercial insurance addressable market
PBM competitive intensity from CVS Health/Aetna, UnitedHealth/OptumRx vertical integration creating captive volume advantages and data synergies
Amazon Pharmacy and Mark Cuban Cost Plus Drug disrupting traditional PBM economics through transparent pricing models
Employer clients increasingly exploring direct contracting with providers and alternative PBM models (pass-through pricing)
Technology-enabled point solutions (GoodRx, Ro, Hims) fragmenting pharmacy and care delivery relationships
Debt refinancing risk with $31B total debt requiring periodic refinancing in potentially higher rate environment
Medical claims reserve adequacy - adverse development in prior years could require $500M-1B reserve strengthening
Pension obligations and retiree healthcare liabilities creating long-duration balance sheet exposure
low - Healthcare services demonstrate counter-cyclical characteristics as medical utilization remains relatively stable through economic cycles. Employer-sponsored insurance (majority of membership) shows minimal elasticity during recessions as benefits are core compensation. PBM revenue tied to prescription volumes driven by chronic disease prevalence and aging demographics rather than GDP growth. However, individual exchange membership and elective procedures show modest pro-cyclical sensitivity.
Rising rates create modest headwind through higher financing costs on $31B debt load (0.81 D/E ratio), with each 100bps rate increase adding ~$310M annual interest expense on floating/refinanced debt. However, Cigna benefits from investment income on insurance float and cash balances ($8-10B), partially offsetting borrowing costs. Valuation multiple compression occurs as defensive healthcare stocks compete with risk-free rates for income-oriented investors. Net impact: moderate negative sensitivity to rising rates.
Minimal direct credit exposure as healthcare services operate on short receivable cycles (30-60 days) with diversified payer mix. However, employer client credit quality affects premium collection and potential coverage lapses during severe recessions. PBM business model includes pharmacy payables float providing working capital benefit. Balance sheet carries investment-grade rating (BBB+/Baa1) with manageable leverage.
value - Stock trades at 0.3x P/S and 8.7x EV/EBITDA, below historical averages and peer multiples, attracting value investors focused on FCF generation (11.5% yield) and capital return. The 82% EPS growth and improving margins appeal to GARP investors identifying operational inflection. Defensive healthcare characteristics with 2.2% net margin stability attract risk-averse allocators seeking recession resilience. Limited dividend yield (1.5-2%) reduces pure income investor appeal.
moderate - Beta typically 0.8-1.0 reflecting healthcare services defensive characteristics with occasional volatility spikes around regulatory announcements, PBM legislation proposals, and earnings surprises. Stock demonstrates lower volatility than broader market during economic uncertainty but faces event risk from policy changes and large contract wins/losses.